Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination

Philip C S de Whalley; Matthew D Snape; Emma Plested; Ben Thompson; Elizabeth Nuthall; Omar Omar; Ray Borrow; Andrew J Pollard

doi:10.1136/archdischild-2013-303893

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination

Philip C S de Whalley, Matthew D Snape^*, Emma Plested, Ben Thompson, Elizabeth Nuthall, Omar Omar, Ray Borrow, Andrew J Pollard

^*Corresponding author for this work

Birmingham Clinical Trials Unit

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Abstract

OBJECTIVES: To determine long-term seroprotection after serogroup C meningococcal (MenC) vaccination at the age of 9-12 years, with or without booster vaccination at the age of 13-15 years.

DESIGN: Observational cohort study; follow-on from randomised study.

SETTING: Participants were recruited from English secondary schools (in Oxfordshire and Buckinghamshire).

PARTICIPANTS AND INTERVENTIONS: Participants were primed with MenC CRM-glycoconjugate vaccine at the age of 9-12 years in the UK routine immunisation campaign. In previous studies they were randomised at 13 to 15 years of age to receive a booster dose of MenC-CRM glycoconjugate vaccine (CRM-group) or bivalent meningococcal serogroup A/C polysaccharide vaccine (PS-group), or they received no additional doses of MenC vaccine (control group). In this follow-on study, a blood sample was obtained 11 years after primary immunisation. Of 531 individuals eligible to participate, 134 were enrolled, and 124 were included in the analysis.

MAIN OUTCOME MEASURES: MenC serum bactericidal antibody (SBA) geometric mean titre; proportion of participants with SBA titre ≥8 (putative protective threshold).

RESULTS: Median ages at priming, boosting and blood sampling were 10.61, 14.42 and 22.11 years, respectively. Geometric mean titres for MenC SBA were: CRM group 1373 (95% CI 954 to 1977); PS group 1024 (687 to 1526); and controls 284 (167 to 483). SBA titres ≥8 were present in 50/54 (92.6%) controls and 70/70 (100%) boosted individuals.

CONCLUSIONS: The planned introduction in the UK of an adolescent booster of MenC conjugate vaccine in 2013 is likely to provide sustained protection against MenC disease.

TRIAL REGISTRATION: Registered on ClinicalTrials.gov (NCT01459432).

Original language	English
Pages (from-to)	686-691
Number of pages	6
Journal	Archives of Disease in Childhood
Volume	98
Issue number	9
Early online date	13 Jul 2013
DOIs	https://doi.org/10.1136/archdischild-2013-303893
Publication status	Published - Sept 2013

Keywords

Adolescent
Child
Cohort Studies
England
Female
Follow-Up Studies
Humans
Immunization, Secondary/methods
Male
Meningococcal Infections/immunology
Meningococcal Vaccines/administration & dosage
Neisseria meningitidis, Serogroup C/immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/archdischild-2013-303893

Cite this

@article{4e6e28f2a3d542b7b247030bf71f7017,

title = "Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination",

abstract = "OBJECTIVES: To determine long-term seroprotection after serogroup C meningococcal (MenC) vaccination at the age of 9-12 years, with or without booster vaccination at the age of 13-15 years.DESIGN: Observational cohort study; follow-on from randomised study.SETTING: Participants were recruited from English secondary schools (in Oxfordshire and Buckinghamshire).PARTICIPANTS AND INTERVENTIONS: Participants were primed with MenC CRM-glycoconjugate vaccine at the age of 9-12 years in the UK routine immunisation campaign. In previous studies they were randomised at 13 to 15 years of age to receive a booster dose of MenC-CRM glycoconjugate vaccine (CRM-group) or bivalent meningococcal serogroup A/C polysaccharide vaccine (PS-group), or they received no additional doses of MenC vaccine (control group). In this follow-on study, a blood sample was obtained 11 years after primary immunisation. Of 531 individuals eligible to participate, 134 were enrolled, and 124 were included in the analysis.MAIN OUTCOME MEASURES: MenC serum bactericidal antibody (SBA) geometric mean titre; proportion of participants with SBA titre ≥8 (putative protective threshold).RESULTS: Median ages at priming, boosting and blood sampling were 10.61, 14.42 and 22.11 years, respectively. Geometric mean titres for MenC SBA were: CRM group 1373 (95% CI 954 to 1977); PS group 1024 (687 to 1526); and controls 284 (167 to 483). SBA titres ≥8 were present in 50/54 (92.6%) controls and 70/70 (100%) boosted individuals.CONCLUSIONS: The planned introduction in the UK of an adolescent booster of MenC conjugate vaccine in 2013 is likely to provide sustained protection against MenC disease.TRIAL REGISTRATION: Registered on ClinicalTrials.gov (NCT01459432).",

keywords = "Adolescent, Child, Cohort Studies, England, Female, Follow-Up Studies, Humans, Immunization, Secondary/methods, Male, Meningococcal Infections/immunology, Meningococcal Vaccines/administration & dosage, Neisseria meningitidis, Serogroup C/immunology",

author = "{de Whalley}, {Philip C S} and Snape, {Matthew D} and Emma Plested and Ben Thompson and Elizabeth Nuthall and Omar Omar and Ray Borrow and Pollard, {Andrew J}",

year = "2013",

month = sep,

doi = "10.1136/archdischild-2013-303893",

language = "English",

volume = "98",

pages = "686--691",

journal = "Archives of Disease in Childhood",

issn = "0003-9888",

publisher = "BMJ Publishing Group",

number = "9",

}

TY - JOUR

T1 - Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination

AU - de Whalley, Philip C S

AU - Snape, Matthew D

AU - Plested, Emma

AU - Thompson, Ben

AU - Nuthall, Elizabeth

AU - Omar, Omar

AU - Borrow, Ray

AU - Pollard, Andrew J

PY - 2013/9

Y1 - 2013/9

N2 - OBJECTIVES: To determine long-term seroprotection after serogroup C meningococcal (MenC) vaccination at the age of 9-12 years, with or without booster vaccination at the age of 13-15 years.DESIGN: Observational cohort study; follow-on from randomised study.SETTING: Participants were recruited from English secondary schools (in Oxfordshire and Buckinghamshire).PARTICIPANTS AND INTERVENTIONS: Participants were primed with MenC CRM-glycoconjugate vaccine at the age of 9-12 years in the UK routine immunisation campaign. In previous studies they were randomised at 13 to 15 years of age to receive a booster dose of MenC-CRM glycoconjugate vaccine (CRM-group) or bivalent meningococcal serogroup A/C polysaccharide vaccine (PS-group), or they received no additional doses of MenC vaccine (control group). In this follow-on study, a blood sample was obtained 11 years after primary immunisation. Of 531 individuals eligible to participate, 134 were enrolled, and 124 were included in the analysis.MAIN OUTCOME MEASURES: MenC serum bactericidal antibody (SBA) geometric mean titre; proportion of participants with SBA titre ≥8 (putative protective threshold).RESULTS: Median ages at priming, boosting and blood sampling were 10.61, 14.42 and 22.11 years, respectively. Geometric mean titres for MenC SBA were: CRM group 1373 (95% CI 954 to 1977); PS group 1024 (687 to 1526); and controls 284 (167 to 483). SBA titres ≥8 were present in 50/54 (92.6%) controls and 70/70 (100%) boosted individuals.CONCLUSIONS: The planned introduction in the UK of an adolescent booster of MenC conjugate vaccine in 2013 is likely to provide sustained protection against MenC disease.TRIAL REGISTRATION: Registered on ClinicalTrials.gov (NCT01459432).

AB - OBJECTIVES: To determine long-term seroprotection after serogroup C meningococcal (MenC) vaccination at the age of 9-12 years, with or without booster vaccination at the age of 13-15 years.DESIGN: Observational cohort study; follow-on from randomised study.SETTING: Participants were recruited from English secondary schools (in Oxfordshire and Buckinghamshire).PARTICIPANTS AND INTERVENTIONS: Participants were primed with MenC CRM-glycoconjugate vaccine at the age of 9-12 years in the UK routine immunisation campaign. In previous studies they were randomised at 13 to 15 years of age to receive a booster dose of MenC-CRM glycoconjugate vaccine (CRM-group) or bivalent meningococcal serogroup A/C polysaccharide vaccine (PS-group), or they received no additional doses of MenC vaccine (control group). In this follow-on study, a blood sample was obtained 11 years after primary immunisation. Of 531 individuals eligible to participate, 134 were enrolled, and 124 were included in the analysis.MAIN OUTCOME MEASURES: MenC serum bactericidal antibody (SBA) geometric mean titre; proportion of participants with SBA titre ≥8 (putative protective threshold).RESULTS: Median ages at priming, boosting and blood sampling were 10.61, 14.42 and 22.11 years, respectively. Geometric mean titres for MenC SBA were: CRM group 1373 (95% CI 954 to 1977); PS group 1024 (687 to 1526); and controls 284 (167 to 483). SBA titres ≥8 were present in 50/54 (92.6%) controls and 70/70 (100%) boosted individuals.CONCLUSIONS: The planned introduction in the UK of an adolescent booster of MenC conjugate vaccine in 2013 is likely to provide sustained protection against MenC disease.TRIAL REGISTRATION: Registered on ClinicalTrials.gov (NCT01459432).

KW - Adolescent

KW - Child

KW - Cohort Studies

KW - England

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Immunization, Secondary/methods

KW - Male

KW - Meningococcal Infections/immunology

KW - Meningococcal Vaccines/administration & dosage

KW - Neisseria meningitidis, Serogroup C/immunology

U2 - 10.1136/archdischild-2013-303893

DO - 10.1136/archdischild-2013-303893

M3 - Article

C2 - 23853000

SN - 0003-9888

VL - 98

SP - 686

EP - 691

JO - Archives of Disease in Childhood

JF - Archives of Disease in Childhood

IS - 9

ER -

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this